We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

Cutaneous Leishmaniasis Drugs Market

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

What is Cutaneous Leishmaniasis Drugs?
Cutaneous leishmaniasis is a parasitic disease. It is spread by the female sandfly, which occurs in the new world and the old world. The drugs approved for cutaneous leishmaniasis treatment include fluconazole, tablet azole antifungals-systemic, Diflucan, Diflucan tablet azole antifungals-systemic, impavido, miltefosine capsule, pentam 300 solution, reconstituted, off and pentamidine 300 mg solution for injection antiprotozoal agents are.

Global Cutaneous Leishmaniasis Drugs Market Outlook
About 95% of cutaneous leishmaniasis cases occur in the Americas, the Mediterranean Basin, the Middle East, and Central Asia. In 2017 over 95% of new cutaneous leishmaniasis cases occurred in six countries: Brazil, Colombia, Afghanistan, Algeria, Iran, Iraq, and the Syrian Arab Republic. According to the World Health Organization, it is anticipated that between 600 000 to 1 million new cases arise worldwide yearly.
Cutaneous leishmaniasis cases have increased intensely in Syria and neighbouring countries due to the conflict-related displacement of Syrians. Advancement in drug therapies to provide a new treatment for cutaneous leishmaniasis. The current strategy is to control this disease mainly based on chemotherapy, presently used therapies against cutaneous leishmaniasis lead to complete cure. However, they associate with many limitations, efficacy remains hindered by the patient's age and immune system.
Lack of awareness, high cost of treatment and prolong treatment span hinders the growth of the market. World Health Organization (WHO) considers leishmaniasis to be one of the main neglected diseases in the world, affecting mostly the poor population of underdeveloped and developing countries.

Global Cutaneous Leishmaniasis Drugs Market Competitive Landscape
The "Global Cutaneous Leishmaniasis Drugs Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as GlaxoSmithKline, Novartis, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Albert David, Profounda, Knight Therapeutics and Johnson & Johnson. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.

Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.

1. INTRODUCTION OF GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources

4. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE
5.1. Overview
5.2. Pentavalent Antimonials
5.3. Antifungal Drugs
5.4. Anti-Leishmanial/Antimicrobial Drugs

6. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.2. Hospitals Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies

7. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
7.5.1. Latin America
7.5.2. Middle East & Africa

8. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. GlaxoSmithKline
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Novartis
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Sanofi
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. Gilead Sciences
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Bristol-Myers Squibb
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
9.6. Albert David
9.6.1. Overview
9.6.2. Financial Performance
9.6.3. Product Outlook
9.6.4. Key Developments
9.7. Profounda
9.7.1. Overview
9.7.2. Financial Performance
9.7.3. Product Outlook
9.7.4. Key Developments
9.8. Knight Therapeutics
9.8.1. Overview
9.8.2. Financial Performance
9.8.3. Product Outlook
9.8.4. Key Developments
9.9. Johnson & Johnson
9.9.1. Overview
9.9.2. Financial Performance
9.9.3. Product Outlook
9.9.4. Key Developments

10. Appendix
10.1. Related Reports

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved